Flurizan Phase II Trial Update

Easy bourse - NEWS: "Myriad Genetics Inc.'s (MYGN) Flurizan drug 'significantly' reduced the number of psychiatric events Alzheimer's patients experienced by 60%, according to a Phase II trial conducted by the Medical University of South Carolina. "